Gene Therapy Strategies for Inhibition of HIV

  • Magnús Gottfredsson


Most of the HIV proteins and virtually every stage in the HIV life cycle can be viewed as a potential site for inhibition. Several of the HIV proteins have been successfully inhibited in vitro and in T cell lines. However, challenging transduced primary T cells and macrophages with diverse strains of HIV is a more realistic system to test and compare the effectiveness of different gene therapy approaches. With several clinical trials planned or underway, the field of gene therapy research for HIV disease is very active, representing 18% of patients undergoing clinical gene therapy trials.1 These advances parallel the remarkable progress in stem cell biology in the past 2–3 years.2,3 In the future, once an ideal combination of anti-HIV genes has been identified, stem cells could be made resistant by one-time delivery of potent combinations of antiviral genes, thereby reconstituting an immune system durably protected from rampant viral multiplication. This chapter reviews different gene therapy approaches that have been taken to inhibit HIV replication, using either viral components or cellular proteins as targets.


Human Immunodeficiency Virus Human Immunodeficiency Virus Type Human Immunodeficiency Virus Infection Human Immunodeficiency Virus Infected Patient Gene Therapy Strategy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Marcel T, Grausz JD. The TMC worldwide gene therapy enrollment report end 1996. Hum Gene Ther 1997; 8: 775–800.Google Scholar
  2. 2.
    Gervaix A, Li X, Kraus G, Wong-Staal F. Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J Virol 1997; 71:3048–3053.Google Scholar
  3. 3.
    Paillard F. The use of peripheral blood hematopoietic progenitors for human immunodeficiency virus gene therapy. Hum Gene Ther 1997; 8: 2170–2172.PubMedGoogle Scholar
  4. 4.
    Yu M, Poeschla E, Yamada O. In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1. Virology 1995; 206:381–386.Google Scholar
  5. 5.
    Maciejewski JP, Weichold FF, Young NS. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nature Med 1995; 1: 667–673.Google Scholar
  6. 6.
    Bordier B, Helene C, Barr PJ, Litvak S, Sarih-Cottin L. In vitro effect of antisense oligonucleotides on human immunodeficiency virus type 1 reverse transcription. Nucleic Acids Res 1992; 20: 5999-6006.Google Scholar
  7. 7.
    Craigie R, Hickman AB, Engelman A. Integrase. In: Kam J, ed. HIV. Biochemistry, molecular biology and drug discovery. Vol. 2. Oxford: Oxford University Press, 1995: 53–71.Google Scholar
  8. 8.
    Sioud M, Drlica K. Prevention of human immunodeficiency virus type 1 integrase expression in Escherichia coli by a ribozyme. Proc Natl Acad Sci USA 1991; 88:7303-7307.Google Scholar
  9. 9.
    Levy-Mintz P, Duan L, Zhang H. Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J Virol 1996; 70: 8821–8832.PubMedGoogle Scholar
  10. 10.
    Berkhout B, Silverman RH, Jeang K-T. Tat Trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 1990; 59273–282.Google Scholar
  11. 11.
    Selby MJ, Peterlin BM. Trans-Activation by HIV-1 Tat via a heterologous RNA binding protein. Cell 1990; 62: 769–776.PubMedCrossRefGoogle Scholar
  12. 12.
    Caputo A, Grossi MP, Rossi C. Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region. Gene Therapy 1996; 3: 235–245.Google Scholar
  13. 13.
    Green M, Ishino M, Loewenstein PM. Mutational analysis of HIV-1 Tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 1989; 58: 215–223.PubMedCrossRefGoogle Scholar
  14. 14.
    Modesti N, Garcia J, Debouck C, Peterlin M, Gaynor R. Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. New Biol 1991; 3: 759–768.Google Scholar
  15. 15.
    Pearson L, Garcia J, Wu F, Modesti N, Nelson J, Gaynor R. A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci USA 1990; 875079-5083.Google Scholar
  16. 16.
    Lo KMS, Biasolo MA, Dehni G, Palu G, Haseltine WA. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 1992; 190: 176–183.PubMedCrossRefGoogle Scholar
  17. 17.
    Liu D, Donegan J, Nuovo G, Mitra D, Laurence J. Stable human immunodeficiency virus type 1 (HIV-1) resistance in transformed CD4+ monocytic cells treated with multitargeting HIV-1 antisense sequences incorporated into U1 snRNA. J Virol 1997; 71: 4079–4085.Google Scholar
  18. 18.
    Rosenzweig M, Marks DF, Hempel D, Lisziewicz J, Johnson RP. Transduction of CD34+ hematopoietic progenitor cells with an antitat gene protects T cell and macrophage progeny from AIDS virus infection. J Virol 1997; 71: 2740–2746.PubMedGoogle Scholar
  19. 19.
    Chatterjee S, Johnson PR, Wong KK Jr. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science 1992; 258: 1485–1488.PubMedCrossRefGoogle Scholar
  20. 20.
    Biasolo MA, Radelli A, Del Pup L, Franchin E, De Giuli-Morghen C, Palu G. A new antisense tRNA construct for the genetic tratment of human immunodeficiency virus type 1 infection. J Virol 1996; 70: 2154–2161.PubMedGoogle Scholar
  21. 21.
    Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Analysis of trans-acting response decoy RNA-mediated inhibition of human immuodeficiency virus type 1 transactivation. J Virol 1991; 65: 6811–6816.PubMedGoogle Scholar
  22. 22.
    Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990; 63: 601–608.PubMedCrossRefGoogle Scholar
  23. 23.
    Lee SW, Gallardo HF, Smith C, Gilboa E. Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Therapy 1995; 2377-384.Google Scholar
  24. 24.
    Lori F, Lisziewicz J, Smythe J. Rapid protection against human immunodeficiency virus type 1 (HIV-1) replication mediated by high efficiency nonretroviral delivery of genes interfering with HIV-1 tat and gag. Gene Therapy 1994; 127-31.Google Scholar
  25. 25.
    Lisziewicz J, Rappaport J, Dhar R. Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression. New Biol 1991; 3: 82–89.Google Scholar
  26. 26.
    Lisziewics J, Sun D, Smythe J. Inhibition of human immunodeficiency virus type i replication by regulated expression of polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci USA 1993; 9o: 800o - 8004.Google Scholar
  27. 27.
    Bohjanen PR, Colvin RA, Puttarju M, Been MD, Garcia-Blanco MA. A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription. Nucleic Acids Res 1996; 24: 3733–3738.Google Scholar
  28. 28.
    Good PD, Krikos AJ, Li SXL. Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther 1997; 4:45-54.Google Scholar
  29. 29.
    Bohjanen PR, Liu Y, Garcia-Blanco MA. TAR RNA decoys inhibit Tat-activated HIV-1 transcription after preinitiation complex formation. Nucleic Acids Res 1997; 25:4481-4486.Google Scholar
  30. 30.
    Sun LQ, Wang L, Gerlach WL, Symonds G. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Nucleic Acids Res 1995; 23:2909-2913.Google Scholar
  31. 31.
    Malim MH, Bohnlein S, Hauber J, Cullen BR. Functional dissection of the HIV-1 Rev trans-activator—derivation of a trans-dominant repressor of Rev function. Cell 1989; 58: 205–214.Google Scholar
  32. 32.
    Escaich S, Kalfglou C, Plavec I, Kaushal S, Mosca JD, Bohnlein E. RevM10-mediated inhibition of HIV-1 replication in chronically infected T cells. Human Gene Ther 1995; 6:625-634.Google Scholar
  33. 33.
    Liu J, Wofferdin C, Yang ZY, Nabel GJ. Regulated expression of a dominant negative form of rev improves resistance to HIV replication in T cells. Gene Therapy 1994; 132-37.Google Scholar
  34. 34.
    Malim MH, Freimuth WW, Liu J. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med 1992; 176: 1197–1201.Google Scholar
  35. 35.
    Ragheb JA, Bressler P, Daucher M. Analysis of trans-dominant mutants of the HIV type 1 rev protein for their ability to inhibit rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics. AIDS Res Hum Retroviruses 1995; 11:1343-1353.Google Scholar
  36. 36.
    Wofferdin C, Yang ZY, Udaykumar. Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. Proc Natl Acad Sci USA 1994; 91: 11581–11585.Google Scholar
  37. 37.
    Wofferdin C, Ranga U, Yang ZY, Xu L, Nabel GJ. Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci USA 1996; 93:2889-2894.Google Scholar
  38. 38.
    Nabel GJ, Fox BA, Post L, Thompson CB, Wofferdin C. A molecular genetic intervention for AIDS-Effects of a transdominant negative form of rev. Human Gene Ther 1994; 5: 79–92.Google Scholar
  39. 39.
    Plavec I, Agarwal M, Ho KE. High transdominant RevMio protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: Implication for gene therapy of AIDS. Gene Ther 1997; 4128–139.Google Scholar
  40. 40.
    Qian X, Chen Z, Zhang J, Rabson AB, Krug RM. New approach for inhibiting REV function and HIV-1 production using the influenza virus NS1 protein. Proc. Natl. Acad. Sci. USA 1996; 938873–8877.Google Scholar
  41. 41.
    Li G, Lisziewicz J, Sun D. Inhibition of Rev activity and human immunodeficiency virus type i replication by antisense oligodeoxynucleotide phosphothioate analogs directed against the Rev-response element. J Virol 1993; 67: 6882–6888.Google Scholar
  42. 42.
    Lisziewicz J, Sun D, Klotman M, Agrawal S, Zamecnik P, Gallo R. Specific inhibition of human immunodeficiency virus type i replication by antisense oligonucleotides: An in vitro model for treatment. Proc Nail Acad Sci USA 1992; 89: 11209–11213.CrossRefGoogle Scholar
  43. 43.
    Sczakiel G, Oppenlander M, Rittner K, Pawlita M. Tat-and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis. J Virol 1992; 66:5576-5581.Google Scholar
  44. 44.
    Bahner I, Kearns K, Hao Q, Smogorzewska EM, Kohn DB. Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long term culture. J Virol. 1996; 704352-4360.Google Scholar
  45. 45.
    Lee TC, Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol 1992; 466-74.Google Scholar
  46. 46.
    Lee SW, Gallardo HF, Gilboa E, Smith C. Inhibition of Human Immunodeficiency Virus Type 1 in human T cells by a potent rev response element decoy consisting of the 13-nucleotide minimal rev-binding domain. J Virol. 1994; 68: 8254–8264.Google Scholar
  47. 47.
    Smith C, Lee S-W, Wong E. Transient protection of human T cells from human immunodeficiency virus type 1 infection by transduction with adeno-associated viral vectors which express RNA decoys. Antiviral Res 1996; 3299-115.Google Scholar
  48. 48.
    Gottfredsson M, Gentry T, Phillips K, Hull S, Gilboa E, Smith C. Suppression of HIV-1 replication in human T cells transduced with an RNA decoy mimicking the rev binding domain of RRE (abstr. I15), 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996. American Society for Microbiology.Google Scholar
  49. 49.
    Duan L, Zhang H, Oakes JW, Bagasra O, Pomerantz RJ. Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficency virus-1 strains. Human Gene Ther 1994; 5: 1315–1324.Google Scholar
  50. 50.
    Duan L, Bagasra O, Laughlin MA, Oakes JW, Pomerantz RJ. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci USA 1994; 91: 5075–5079.Google Scholar
  51. 51.
    Wu Y, Duan L, Zhu M. Binding of intracellular anti-rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition. J Virol 1996; 70: 3290–3297.PubMedGoogle Scholar
  52. 52.
    Kubota S, Duan L, Furuta RA, Hatanaka M, Pomerantz RJ. Nuclear preservation and cytoplasmic degradation of human immunodeficiency virus type 1 Rev protein. J Virol 1996; 70: 1282–1287.Google Scholar
  53. 53.
    Inouye RT, Du B, Boldt-Houle D. Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adenoassociated virus vector. J Virol 1997; 71: 4071–4078.PubMedGoogle Scholar
  54. 54.
    Yamada O, Kraus G, Leavitt MC, Yu M, Wong-Staal F. Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells. Virology 1994; 205: 121–126.Google Scholar
  55. 55.
    Zhou C, Bahner IC, Larson GP, Zaia JA, Rossi JJ, Kohn DB. Inhibition of HIV-1 in human T lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 1994; 149:33-39.Google Scholar
  56. 56.
    Kestler HW III, Ringler DJ, Mori K. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991; 65: 651–662.PubMedCrossRefGoogle Scholar
  57. 57.
    Aiken C, Konner J, Landau NR, Lenburg ME, Trono D. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 1994; 76853-864.Google Scholar
  58. 58.
    Kerkau T, Schmitt-Landgraf R, Schimpl A, Wecker E. Down-regulation of HLA class I antigens in HIV-1-infected cells. AIDS Res Hum Retroviruses 1989; 5: 613–620.PubMedCrossRefGoogle Scholar
  59. 59.
    Schwartz O, Maréchal V, Le Gall S, Lemonnier F, Heard J-M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 nef protein. Nature Med 1996; 2338-342.Google Scholar
  60. 60.
    Deacon NJ, Tsykin A, Solomon A. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270988-991.Google Scholar
  61. 61.
    Larsson S, Hotchkiss G, Su J. A novel ribozyme target site located in the HIV-1 Nef open reading frame. Virology 1996; 219: 161–169.PubMedCrossRefGoogle Scholar
  62. 62.
    Walker RE, Blease RM, Davey RT, Falloon J, Mullen C, Polis MA. A phase I/II pilot study of the safety of the adoptive transfer of syngeneic gene-modified cytotoxic T lymphocytes in HIV-infected identical twins. Human Gene Ther 1996; 7: 367–400.CrossRefGoogle Scholar
  63. 63.
    Ojwang JO, Hampel A, Looney DJ, Wong-Staal F, Rappaport J. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci USA 1992; 89: 10802–10806.PubMedCrossRefGoogle Scholar
  64. 64.
    Dropulic B, Lin NH, Martin MA, Jeang K-T. Functional characterization of a U5 ribozyme: Intracellular suppression of human immunodeficiency virus type 1 expression. J Virol 1992; 66: 1432–1441.PubMedGoogle Scholar
  65. 65.
    Yamada O, Yu M, Yee JK, Kraus G, Looney D, Wong-Staal F. Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Therapy 1994; 1: 38–45.Google Scholar
  66. 66.
    Yu M, Ojwang J, Yamada O. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus Type 1. Proc Natl Acad Sci USA 1993; 90: 6340–6344.Google Scholar
  67. 67.
    Weerasinghe M, Liem SE, Asad S, Read SE, Joshi S. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol 1991; 65:5531-5534.Google Scholar
  68. 68.
    Leavitt MC, Yu M, Yamada O. Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Human Gene Therapy 1994; 5: 1115–1120.Google Scholar
  69. 69.
    Yu M, Leavitt MC, Maruyama M. Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1995; 92:669-703.Google Scholar
  70. 70.
    Trono D, Feinberg MB, Baltimore D. HIV-gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 1989; 59: 113–120.PubMedCrossRefGoogle Scholar
  71. 71.
    Sczakiel G, Pawlita M, Kleinheinz A. Specific inhibition of human immunodeficiency virus type i replication by RNA transcribed in sense and antisense from the 5’-leader/gag region. Biochem Biophys Res Comm 1990; 169: 643–651.PubMedCrossRefGoogle Scholar
  72. 72.
    Sczakiel G, Pawlita M. Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA. J Virol 1991; 65: 468–472.PubMedGoogle Scholar
  73. 73.
    Veres G, Escaich S, Baker J. Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type i gag gene inhibits viral replication in human CD4+ lymphocytes. J Virol 1996; 70: 8792–8800.PubMedGoogle Scholar
  74. 74.
    Sarver N, Cantin EM, Chang PS. Ribozymes as potential antiHIV-1 therapeutic agents. Science 1990; 247: 1222–1225.PubMedCrossRefGoogle Scholar
  75. 75.
    Rice WG, Supko JG, Malspeis L. Inhibitors of HIV nucleoprotein Zinc fingers as candidates for the treatment of AIDS. Science 1995; 270: 1194–1197.PubMedCrossRefGoogle Scholar
  76. 76.
    Mebatsion T, Finke S, Weiland F, Conzelman K-K. A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 1997; 90:841–847.Google Scholar
  77. 77.
    Schnell MJ, Johnson JE, Buonocore L, Rose JK. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 1997; 90:849-857.Google Scholar
  78. 78.
    Marasco WA, Haseltine WA, Chen S. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp12o single-chain antibody. Proc Natl Acad Sci USA 1993; 90: 7889–7893.Google Scholar
  79. 79.
    Chen C-J, Banerjea AC, Harmison GG, Haglund K, Schubert M. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication—potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res 1992; 204581–4589.Google Scholar
  80. 80.
    Babé LM, Rosé J, Craik CS. Trans-dominant inhibitory immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation. Proc Natl Acad Sci USA 1995; 92: 10069–10073.Google Scholar
  81. 81.
    Junker U, Escaich S, Plavec I. Intracellular expression of human immunodeficiency virus type 1 (HIV-1) protease variants inhibits replication of wild-type and protease inhibitor-resistant HIV-1 strains in human T cell lines. J Virol 1996; 70:7765-7772.Google Scholar
  82. 82.
    Serio D, Rizvi TA, Cartas M. Development of a novel anti-HIV1 agent from within: Effect of chimeric vpr-containing protease cleavage site residues on virus replication. Proc Natl Acad Sci USA 1997; 94:3346-3351.Google Scholar
  83. 83.
    Trono D. HIV accessory proteins: leading roles for the supporting cast. Cell 1995; 82: 189–192.Google Scholar
  84. 84.
    Miller RH, Turk SR, Black RJ, Bridges S, Sarver N. Conference summary: Novel HIV therapies—from discovery to clinical proof of concept. AIDS Res Hum Retroviruses 1996; 12: 859–865.PubMedCrossRefGoogle Scholar
  85. 85.
    Heinzinger NK, Bukrinsky MI, Haggerty SA. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994; 917311-7315.Google Scholar
  86. 86.
    Miller RH, Sarver N. HIV accessory proteins as therapeutic targets. Nature Med 1997; 4: 389–394.Google Scholar
  87. 87.
    Wu X, Liu H, Xiao H. Targeting foreign proteins to human immunodeficiency virus particles via fusion with vpr and vpx. J Virol 1995; 69: 3389–3398.Google Scholar
  88. 88.
    Lever A, Gottlinger H, Haseltine W, Sodroski J. Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol 1989; 63: 4085–4087.PubMedGoogle Scholar
  89. 89.
    Mann R, Baltimore D. Varying the position of a retrovirus packaging sequence results in the encapsidation of both unspliced and spliced RNAs. J Virol 1985; 54: 401–407.Google Scholar
  90. 90.
    Sun L-Q, Warrilow D, Wang L, Witherington C, Macpherson J, Symonds G. Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type 1 replication in permissive cell lines. Proc Natl Acad Sci USA 1994; 91: 9715–9719.Google Scholar
  91. 91.
    Caruso M, Klatzmann D. Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected population. Proc Natl Acad Sci USA 1992; 89: 182–186.PubMedCrossRefGoogle Scholar
  92. 92.
    Brady HJM, Miles CG, Pennington DJ, Dzierzak EA. Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses. Proc Nail Acad Sci USA 1994; 91: 356–369.Google Scholar
  93. 93.
    Venkatesh LK, Arens MQ, Subramanian T, Chinnadurai G. Selective inhibition of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector. Proc Natl Acad Sci USA 1990; 87:8746-8750.Google Scholar
  94. 94.
    Harrison GS, Long CJ, Curiel TJ, Maxwell F, Maxwell IH. Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphteria toxin A chain gene. Human Gene Ther 1992; 3:461-469.Google Scholar
  95. 95.
    Harrison GS, Long CJ, Maxwell F, Glode LM, Maxwell IH. Inhibition of HIV production in cells containing an integrated, HIV-regulated diptheria toxin A chain gene. AIDS Res Hum Retroviruses 1992.Google Scholar
  96. 96.
    Winters MA, Merigan TC. Continuous presence of CD4–PE4o is required for antiviral activity against single-passage HIV isolates and infected peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1993; 9: 1091–1096.Google Scholar
  97. 97.
    Hamouda T, McPhee R, Hsia S-C, Read S, Holland TC, King SR. Inhibition of human immunodeficiency virus replication by the herpes simplex virus virion host shutoff protein. J Virol 1997; 71: 5521–5527.Google Scholar
  98. 98.
    Dalgleish AG, Beverley PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312: 763–767.Google Scholar
  99. 99.
    Daar ES, Li XL, Moudgil T, Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary Human Immunodeficiency Virus Type 1 isolates. Proc Natl Acad Sci USA 199o; 87: 6574–6578.Google Scholar
  100. 100.
    Watanabe M, Chen ZW, Tsubota H, Lord CI, Levine CG, Letvin NL. Soluble human CD4 elicits antibody responses in rhesus monkeys that inhibits simian immunodeficiency virus replication. Proc Natl Acad Sci USA 1991; 88: 120–124.PubMedCrossRefGoogle Scholar
  101. 101.
    Watanabe M, Boyson JE, Lord CI, Letvin NL. Chimpanzees immunized with recombinant soluble CD4 develop anti-self CD4 antibody responses with anti-human immunodeficiency virus activity. Proc Natl Acad Sci USA 1992; 89:5103-5107.Google Scholar
  102. 102.
    Buonocore L, Rose JK. Prevention of HIV-1 glycoprotein transport by soluble CD4 retained in the endoplasmic reticulum. Nature 1990; 345:625-628.Google Scholar
  103. 103.
    Buoncore L, Rose JK. Blockade of human immunodeficiency virus type 1 production in CD4+ T cells by an intracellular CD4 expressed under control of the viral long terminal repeat. Proc Natl Acad Sci USA 1993; 90:2695-2699.Google Scholar
  104. 104.
    Alkhatib G, Combardiere C, Broder CC. CC CKR5: A RANTES, MIP-1a, MIP-1ß receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-1958.Google Scholar
  105. 105.
    Choe H, Farzan M, Sun Y. The ß-Chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135–1148.PubMedCrossRefGoogle Scholar
  106. 106.
    Deng H, Liu R, Ellmeier W. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996; 381: 661–666.PubMedCrossRefGoogle Scholar
  107. 107.
    Doranz BJ, Rucker J, Yi Y. A dual-tropic primary HIV-1 isolate that uses Fusin and the (3-Chemokine receptors CKR-5, CKR-3, and CKR-2b as Fusion cofactors. Cell 1996; 85: 1149–1158.PubMedCrossRefGoogle Scholar
  108. 108.
    Dragic T, Litwin V, Allaway GP. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667–673.PubMedCrossRefGoogle Scholar
  109. 109.
    Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872–877.PubMedCrossRefGoogle Scholar
  110. 110.
    Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994; 5597-179.Google Scholar
  111. 111.
    Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Indentification of RANTES, MIP1a, and MIP-1ß as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811–1815.Google Scholar
  112. 112.
    Paxton WA, Martin SR, Tse D. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nature Med 1996; 2: 412–417.PubMedCrossRefGoogle Scholar
  113. 113.
    Liu R, Paxton WA, Choe S. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367–377.PubMedCrossRefGoogle Scholar
  114. 114.
    Dean M, Carrington M, Winkler C. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996; 273: 1856–1862.PubMedCrossRefGoogle Scholar
  115. 115.
    Yang AG, Bai X, Huang XF, Yao C, Chen S. Phenotypic knockout of HIV type i chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci USA 1997; 9411567–11572.Google Scholar
  116. 116.
    Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987; 326: 711–713.PubMedCrossRefGoogle Scholar
  117. 117.
    Baeuerle PA, Baltimore D. IxB: a specific inhibitor of the NF-KB transcription factor. Science 1988; 242: 540–546.PubMedCrossRefGoogle Scholar
  118. 118.
    Urban MB, Baeuerle PA. The 65-kD subunit of NF-xB is a receptor for IkB and a modulator of DNA-binding specificity. Genes Dev 1990; 41975-1984.Google Scholar
  119. 119.
    Laspia MF, Rice AP, Mathews MB. Synergy between HIV-1 Tat and adenovirus E1A is principally due to stabilization of transcriptional elongation. Genes Dev 1990; 4: 2397–2408.Google Scholar
  120. 120.
    Wu BY, Wofferdin C, Duckett CS, Ohno T, Nabel GJ. Regulation of human retoviral latency by the NF-xB/IiB family: inhibition of human immunodeficiency virus replication by IxB through a rev-dependent mechanism. Proc. Natl. Acad. Sci. USA 1995; 92: 1480–1484.PubMedCrossRefGoogle Scholar
  121. 121.
    Beauparlant P, Kwon H, Clarke M. Transdominant mutants of IxB block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type i gene expression and virus multiplication. J Virol 1996; 70: 5777–5785.Google Scholar
  122. 122.
    Ruhl M, Himmelspach M, Bahr GM. Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activation. J Cell Biol 1993; 123: 1309–1320.Google Scholar
  123. 123.
    Bevec D, Jaksche H, Oft M. Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A. Science 1996; 271: 1858–1860.Google Scholar
  124. 124.
    Junker U, Bevec D, Barske C. Intracellular expression of cellular eIF-5A mutants inhibits HIV-1 replication in human T cells: a feasibility study. Human Gene Ther 1996; 7: 1861–1869.CrossRefGoogle Scholar
  125. 125.
    Francis ML, Meltzer MS, Gendelman HE. Interferons in the persistence, pathogenesis, and treatment of HIV infection. AIDS Res Hum Retroviruses 1992; 8: 199–207.PubMedCrossRefGoogle Scholar
  126. 126.
    Baca-Regen L, Heinzinger N, Stevenson M, Gendelman HE. Alpha interferon-induced antiretroviral activites: restriction of viral nucleic acid synthesis and progeny virion production in human immunodeficiency virus type 1-infected monocytes. J Virol 1994; 687559-7565.Google Scholar
  127. 127.
    Constantoulakis P, Campbell M, Felber BK, Nasioulas G, Afonina E, Pavlakis GN. Inhibition of Rev-mediated HIV-1 expression by an RNA binding protein encoded by the Interferon-inducible 9–27 gene. Science 1993; 259: 1314–1318.Google Scholar
  128. 128.
    Vieillard V, Lauret E, Rousseau V, De Maeyer E. Blocking of retroviral infection at a step prior to reverse transcription in cells transformed to constitutively express interferon beta. Proc Natl Acad Sci USA 1994; 91:2689-2693.Google Scholar
  129. 129.
    Vieillard V, Lauret E, Maguer V. Autocrine interferon-ß synthesis for gene therapy of HIV infection: increased resistance to HIV-1 in lymphocytes from healthy and HIV-infected individuals. AIDS 1995; 9: 1221–1228.Google Scholar
  130. 130.
    Schnittman SM, Vogel S, Baseler M, Lane HC, Davey RT. A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with Human Immunodeficiency Virus infection. J Infect Dis 1994; 169: 981–989.Google Scholar
  131. 131.
    Perkins ND, Agranoff AB, Duckett CS, Nabel GJ. Transcription factor AP-2 regulates Human Immunodeficiency Virus Type 1 gene expression. J Virol 1994; 68: 6820–6823.Google Scholar
  132. 132.
    Jones KA, Kadonaga JT, Luciw PA, Tjian R. Activation of the AIDS retrovirus promoter by the cellular transcription factor, Spi. Science 1986; 232:755-759.Google Scholar
  133. 133.
    Perkins ND, Agranoff AB, Pascal E, Nabel GJ. An interaction between the DNA-binding domains of Re1A(p65) and Spi mediates human immunodeficiency virus gene activation. Mol Cell Biol 1994; 14: 6570–6583.Google Scholar
  134. 134.
    Stade K, Ford CS, Guthrie C, Weis K. Exportin 1 (Crmip) is an essential nuclear export factor. Cell 1997; 90: 1041–1050.Google Scholar
  135. 135.
    Fornerod M, Ohno M, Yoshida M, Mattaj IW. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997; 90: 1051–1060.Google Scholar
  136. 136.
    Ullman KS, Powers MA, Forbes DJ. Nuclear export receptors: From importin to exportin. Cell 1997; 90:967-970.Google Scholar
  137. 137.
    Bogerd HP, Fridell RA, Madore S, Cullen BR. Identification of a novel cellular cofactor for the rev/rex class of retroviral regulatory proteins. Cell 1995; 82485–494.Google Scholar
  138. 138.
    Powell DM, Amaral MC, Wu JY, Maniatis T, Greene WC. HIV Rev-dependent binding of SF2/ASF to the Rev response element: possible role in Rev-mediated inhibition of HIV RNA splicing. Proc Natl Acad Sci USA 1997; 94: 973–978.Google Scholar
  139. 139.
    Yuyama N, Ohkawa J, Koguma T, Shirai M, Taira K. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5’- and 3’-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev. Nucleic Acids Res 1994; 22: 5060–5067.Google Scholar
  140. 140.
    Yamada O, Kraus G, Luznik L, Yu M, Wong-Staal F. A chimeric human immunodeficiency virus type 1 (HIV-1) minimal rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J Virol 1996; 70: 1596–1601.PubMedGoogle Scholar
  141. 141.
    Ulich C, Harrich D, Estes P, Gaynor RB. Inhibition of human immunodeficiency virus Type i replication is enhanced by a combination of transdominant tat and rev proteins. J Virol 1996; 70: 4871–4876.PubMedGoogle Scholar
  142. 142.
    Ohkawa J, Yuyama N, Takebe Y, Nishikawa S, Taira K. Importance of independence in ribozyme reactions: kinetic behavior of trimmed and simply connected ribozymes with potential activity against human immunodeficiency virus. Proc Natl Acad Sci USA 1993; 90: 11302–11306.Google Scholar
  143. 143.
    Kinter AL, Bende SM, Hardy EC, Jackson R, Fauci AS. Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci USA 1995; 92: 10985–10989.Google Scholar
  144. 144.
    Barker E, Mackewicz CE, Levy JA. Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: Implications for long-term survival. Proc Natl Acad Sci USA 1995; 92: 11135–11139.Google Scholar
  145. 145.
    Carmichael A, Jin X, Sissons P, Borysiewicz. Quantitative analysis of the human immunodeficiency virus type i (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr Virus in late disease. J Exp Med 1993; 177: 249–256.Google Scholar
  146. 146.
    Kundu SK, Merigan TC. Inverse relationship of CD8+CD11+ suppressor T cells with human immunodeficiency virus (HIV)-specific cellular cytotoxicity and natural killer cell activity in HIV infection. Immunology 1991; 74: 567–571.Google Scholar
  147. 147.
    Koup RA, Safrit JT, Cao Y. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650–4655.Google Scholar
  148. 148.
    Klein MR, van Baalen CA, Holwerda AM. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995; 181: 1365–1372.Google Scholar
  149. 149.
    Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MBA. Virus-specific CD8+ cytotoxic T lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103–6110.Google Scholar
  150. 150.
    Blaese RM. Steps toward gene therapy: 2. Cancer and AIDS. Hosp Pract 1995; 30:37-45.Google Scholar
  151. 151.
    Flowers CC, Wofferdin C, Petryniak J, Yang S, Nabel GJ. Inhibition of recombinant human immunodeficiency virus type 1 replication by a site-specific recombinase. J Virol 1997; 71: 2685–2692.PubMedGoogle Scholar
  152. 152.
    Riddell SR, Elliott M, Lewinsohn DA. T cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med 1996; 2: 216–223.PubMedCrossRefGoogle Scholar
  153. 153.
    Ziegner UHM, Peters G, Jolly DJ. Cytotoxic T lymphocyte induction in asymptomatic HIV-1-infected patients immunized with Retrovector®-transduced autologous fibroblasts expressing HIV-1 IIIB env/rev proteins. AIDS 1995; 9:43-50.Google Scholar
  154. 154.
    Ross G, Erickson R, Knorr D. Gene therapy in the United States: A five year status report. Hum Gene Ther 1996; 7: 1781–1790.PubMedCrossRefGoogle Scholar
  155. 155.
    Baltimore D. The enigma of HIV infection. Cell 1995; 82: 175–176.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Magnús Gottfredsson

There are no affiliations available

Personalised recommendations